Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
20 to 75
Other
27MD02
NCT00154713
Last Modified:
6/12/2008
 
First Published:
3/18/2008
2.
Phase I/II Randomized Study of Cytomegalovirus-Targeted Anti-Tumor Immunotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
DUMC-PRO00003877
Pro00003877, DUMC-8108-07-1R1, NCT00639639
Last Modified:
11/27/2007
 
First Published:
8/18/2006
3.
Phase I Study of CpG 7909 For the Enhancement of Immune Reconstitution in Patients Who Have Undergone Autologous Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
UMN-2003LS014
UMN-0302M41542, UMN-MT2003-03, NCT00369291
4.
Vaccination With Tetanus and KLH to Assess Immune Responses.
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Biomarker/Laboratory analysis, Treatment
Active
18 to 55
NCRR
NCRR-M01RR00400-0626
M01RR00400, NCT00000105
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute